Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
164 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H2 2014', provides an overview of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 7 Global Markets Direct Report Coverage 7 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Overview 8 Therapeutics Development 9 Pipeline Products for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Overview 9 Pipeline Products for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Comparative Analysis 10 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics under Development by Companies 11 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics under Investigation by Universities/Institutes 14 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Unknown Stage Products 18 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Products under Development by Companies 19 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Products under Investigation by Universities/Institutes 22 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Companies Involved in Therapeutics Development 23 Gamida Cell Ltd. 23 Piramal Enterprises Limited 24 Aeolus Pharmaceuticals, Inc. 25 Cleveland BioLabs, Inc. 26 Soligenix, Inc. 27 NeoStem, Inc. 28 Pluristem Therapeutics Inc. 29 Cumberland Pharmaceuticals, Inc. 30 Cellerant Therapeutics, Inc. 31 Humanetics Corporation 32 Meabco A/S 33 ActoKine Therapeutics 34 Priaxon AG 35 ProCertus BioPharm Inc. 36 Angion Biomedica Corp. 37 Onconova Therapeutics, Inc. 38 Avaxia Biologics, Inc. 39 Bolder Biotechnology, Inc. 40 Stemedica Cell Technologies, Inc. 41 Biothera, Inc. 42 Terapio Corporation 43 Neumedicines Inc. 44 RxBio, Inc. 45 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics Assessment 46 Assessment by Monotherapy Products 46 Assessment by Target 47 Assessment by Mechanism of Action 50 Assessment by Route of Administration 53 Assessment by Molecule Type 55 Drug Profiles 57 entolimod - Drug Profile 57 P-276 - Drug Profile 59 NMIL-121 - Drug Profile 61 BIO-300 - Drug Profile 63 SGX-201 - Drug Profile 66 GC-003 - Drug Profile 67 Mesenchymal Stem Cells - Drug Profile 68 AEOL-10150 - Drug Profile 71 recilisib sodium - Drug Profile 74 GC-4403 - Drug Profile 76 rusalatide acetate - Drug Profile 77 SGX-202 - Drug Profile 80 BP-C2 - Drug Profile 81 BB-3 - Drug Profile 82 romyelocel-L - Drug Profile 84 BBT-045 - Drug Profile 85 JP4-039 - Drug Profile 86 PLX-BMP - Drug Profile 88 GC-4419 - Drug Profile 91 Rx-100 - Drug Profile 92 Stem Cell Therapy for Radiation Exposure - Drug Profile 94 BIO-700 - Drug Profile 95 BIO-800 - Drug Profile 96 CLT-009 - Drug Profile 97 PrC-210 - Drug Profile 98 SY-303A - Drug Profile 99 Small Molecules for Radiation Toxicity - Drug Profile 100 AK-1 - Drug Profile 101 Stem Cell Therapy for Acute Radiation Syndrome - Drug Profile 102 Human Ghrelin - Drug Profile 103 ST-7 - Drug Profile 104 m2A2 - Drug Profile 105 Recombinant Human MFG-E8 - Drug Profile 106 BCN-057 - Drug Profile 107 517-PXN - Drug Profile 108 2A-2 - Drug Profile 109 CBLB-613 - Drug Profile 111 RP-239X - Drug Profile 112 AVX-470 - Drug Profile 113 Imprime WGP - Drug Profile 114 BBT-015 - Drug Profile 115 BBT-018 - Drug Profile 116 BBT-007 - Drug Profile 117 AEOL-10171 - Drug Profile 118 Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Musculoskeletal Disorders - Drug Profile 119 Small Molecules to Activate Vitamin D Receptor for Radiation Injury - Drug Profile 120 TPO-7630 - Drug Profile 121 Small Molecule to Inhibit GSK-3 for Acute and Late Radiation Injury - Drug Profile 123 EDL-2000 - Drug Profile 124 RX-101 - Drug Profile 125 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Recent Pipeline Updates 126 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects 150 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Discontinued Products 151 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Product Development Milestones 152 Featured News & Press Releases 152 Appendix 160 Methodology 160 Coverage 160 Secondary Research 160 Primary Research 160 Expert Panel Validation 160 Contact Us 161 Disclaimer 161
List of Tables Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H2 2014 12 Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Comparative Analysis, H2 2014 13 Number of Products under Development by Companies, H2 2014 15 Number of Products under Development by Companies, H2 2014 (Contd..1) 16 Number of Products under Investigation by Universities/Institutes, H2 2014 17 Comparative Analysis by Late Stage Development, H2 2014 18 Comparative Analysis by Clinical Stage Development, H2 2014 19 Comparative Analysis by Early Stage Development, H2 2014 20 Comparative Analysis by Unknown Stage Development, H2 2014 21 Products under Development by Companies, H2 2014 22 Products under Development by Companies, H2 2014 (Contd..1) 23 Products under Development by Companies, H2 2014 (Contd..2) 24 Products under Investigation by Universities/Institutes, H2 2014 25 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Gamida Cell Ltd., H2 2014 26 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Piramal Enterprises Limited, H2 2014 27 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Aeolus Pharmaceuticals, Inc., H2 2014 28 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cleveland BioLabs, Inc., H2 2014 29 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Soligenix, Inc., H2 2014 30 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by NeoStem, Inc., H2 2014 31 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Pluristem Therapeutics Inc., H2 2014 32 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cumberland Pharmaceuticals, Inc., H2 2014 33 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cellerant Therapeutics, Inc., H2 2014 34 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Humanetics Corporation, H2 2014 35 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Meabco A/S, H2 2014 36 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by ActoKine Therapeutics, H2 2014 37 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Priaxon AG, H2 2014 38 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by ProCertus BioPharm Inc., H2 2014 39 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Angion Biomedica Corp., H2 2014 40 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Onconova Therapeutics, Inc., H2 2014 41 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Avaxia Biologics, Inc., H2 2014 42 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Bolder Biotechnology, Inc., H2 2014 43 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Stemedica Cell Technologies, Inc., H2 2014 44 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Biothera, Inc., H2 2014 45 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Terapio Corporation, H2 2014 46 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Neumedicines Inc., H2 2014 47 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by RxBio, Inc., H2 2014 48 Assessment by Monotherapy Products, H2 2014 49 Number of Products by Stage and Target, H2 2014 52 Number of Products by Stage and Mechanism of Action, H2 2014 55 Number of Products by Stage and Route of Administration, H2 2014 57 Number of Products by Stage and Molecule Type, H2 2014 59 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Therapeutics - Recent Pipeline Updates, H2 2014 129 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects, H2 2014 153 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Discontinued Products, H2 2014 154
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
